Lawrence Steinman is Director of 180 Life Sciences Corp.. Currently has a direct ownership of 48,129 shares of ATNF, which is worth approximately $180,002. The most recent transaction as insider was on Jun 01, 2023, when has been sold 18,000 shares (Common Stock) at a price of $1.23 per share, resulting in proceeds of $22,140. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 48.1K
0% 3M change
0% 12M change
Total Value Held $180,002

LAWRENCE STEINMAN Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 01 2023
BUY
Open market or private purchase
$22,140 $1.23 p/Share
18,000 Added 27.22%
48,129 Common Stock
Dec 09 2021
BUY
Open market or private purchase
$21,350 $4.27 p/Share
5,000 Added 0.82%
602,574 Common Stock
Sep 30 2021
BUY
Grant, award, or other acquisition
$31,296 $6.0 p/Share
5,216 Added 0.87%
597,574 Common Stock
Apr 07 2021
BUY
Grant, award, or other acquisition
$138,672 $6.14 p/Share
22,585 Added 3.67%
592,358 Common Stock

Also insider at

BCAB
BioAtla, Inc. Healthcare
KTTA
Pasithea Therapeutics Corp. Healthcare
LS

Lawrence Steinman

Director
Palo Alto, CA

Track Institutional and Insider Activities on ATNF

Follow 180 Life Sciences Corp. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ATNF shares.

Notify only if

Insider Trading

Get notified when an 180 Life Sciences Corp. insider buys or sells ATNF shares.

Notify only if

News

Receive news related to 180 Life Sciences Corp.

Track Activities on ATNF